<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="2180">
  <stage>Registered</stage>
  <submitdate>17/11/2008</submitdate>
  <approvaldate>17/11/2008</approvaldate>
  <nctid>NCT00792558</nctid>
  <trial_identification>
    <studytitle>Ascending Multiple-Dose Study of BMS-817378 in Subjects With Advanced Cancers</studytitle>
    <scientifictitle>A Phase I Ascending Multiple-Dose Study of BMS-817378 in Subjects With Advanced or Metastatic Solid Tumors</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>CA195-001</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Advanced Solid Tumors</healthcondition>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - BMS-817378

Experimental: Single Arm - 


Treatment: drugs: BMS-817378
Capsule, Oral, Dose escalation to a MTD from a starting dose of 25 mg, once daily, until disease progression/subject discontinuation

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>To establish the MTD of BMS-817378 when administered orally on a daily schedule in subjects with advanced cancers</outcome>
      <timepoint>Within the first 21 days after first dose of BMS-817378</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Assess safety and tolerability of multiple doses of BMS-817378 administered orally on a once daily schedule in subjects with advanced or metastatic solid tumors</outcome>
      <timepoint>All time points while subject is on study</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Assess the safety and tolerability of co-administration of a CYP substrate cocktail and BMS-817378 given at or below the MTD (dose expansion cohort)</outcome>
      <timepoint>Day 22 +/-2</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Characterize the pharmacokinetics of BMS-817378 and its active moiety, BMS-794833</outcome>
      <timepoint>Days 1 and 15</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Assess the effects of BMS-817378 and BMS-794833 on blood pressure, heart rate, ECG intervals, and left ventricular ejection fraction</outcome>
      <timepoint>All time points while subject is on study</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Describe preliminary evidence for anti-tumor activity of BMS-817378</outcome>
      <timepoint>Every 6 weeks</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Confirmed diagnosis of advanced non-hematologic malignancy. Dose expansion cohort
             restricted to subjects with advanced or metastatic gastroesophageal cancer, squamous
             cell cancers of the head and neck, and castration resistant prostate cancer

          -  ECOG status 0-1</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  WOCBP unwilling/unable to use acceptable contraception methods, and women pregnant or
             breast feeding

          -  Symptomatic brain metastasis

          -  Uncontrolled or significant cardiovascular disease

          -  History of thromboembolic events or bleeding diathesis in past 6 months

          -  Conditions requiring prophylactic anticoagulation or chronic anti-platelet therapy

          -  Serious non-healing wounds, ulcers or bone fractures in past 3 months

          -  Hemorrhage or bleeding event &gt;= CTCAE grade 3 in past 4 weeks

          -  Proteinuria &gt;= 2+ on dipstick or &gt;= 1gm/24 hours

          -  Concurrent chemotherapy, hormonal therapy, immunotherapy, radiation therapy or therapy
             with any other investigational product

          -  Concurrent herbal, alternative, food supplements, or strong CYP 3A4 inhibitors or
             inducers</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation />
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Single group</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 1</phase>
    <anticipatedstartdate>1/01/2009</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>0</actualsamplesize>
    <recruitmentstatus>Withdrawn</recruitmentstatus>
    <anticipatedlastvisitdate>1/11/2010</anticipatedlastvisitdate>
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>SA,WA</recruitmentstate>
    <hospital>Local Institution - Adelaide</hospital>
    <hospital>Local Institution - Nedlands</hospital>
    <postcode>5000 - Adelaide</postcode>
    <postcode>6009 - Nedlands</postcode>
    <countryoutsideaustralia>
      <country>Singapore</country>
      <state>Singapore</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Bristol-Myers Squibb</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>The purpose of this study is to find the maximum tolerated dose of BMS-817378 in subjects
      with advanced cancers</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT00792558</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Bristol-Myers Squibb</name>
      <address>Bristol-Myers Squibb</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>